Concepedia

Hu Sheng Qian

HS

13

Publications

1K

Citations

13

H-Index

2000

Active since

Affiliations

Boehringer Ingelheim (United States)(Current)

Virginia BioTechnology Research Park

Boehringer Ingelheim (Germany)

Hu Sheng Qian is an author at Boehringer Ingelheim (United States) specializing in medicine, immunology, and atherosclerosis.

ORCID

Top concepts

Publications per year

2000–2022

13

Publications

13

Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle

Alan R. Brooks, Richard N. Harkins, Peiyin Wang et al. · The Journal of Gene Medicine · 2004 · 366 citations

Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension

Rong Shao, Hu Sheng Qian, Samuel E. George et al. · Journal of Clinical Investigation · 2000 · 158 citations · Full text

In vivo selective inhibition of TRPC6 by antagonist BI 749327 ameliorates fibrosis and dysfunction in cardiac and renal disease

Brian L. Lin, Damian Matera, Julia F. Doerner et al. · Proceedings of the National Academy of Sciences · 2019 · 143 citations · Full text

A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 Rat

Carine M. Boustany‐Kari, Paul C. Harrison, Hu Sheng Qian et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 56 citations · Full text

Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice

Harald Petry, A.R. Brooks, Ann E. Orme et al. · Gene Therapy · 2007 · 56 citations

, , +7

Rows per page

1–5 of 13